A recent advance in multiple sclerosis (MS) treatment that has led to improved efficacy has been the development of drugs that effectively block immune cells from entering the central nervous system (CNS). There are serious risks associated with these drugs, however, such as progressive multifocal leukoencephalopathy associated with natalizumab and bradycardia associated with fingolimod, which limit their use in individuals with MS who are identified as being high-risk for these adverse effects. These risks are attributable to relatively unique properties of each drug and therefore new strategies to impede CNS immune cell trafficking may lead to the development of effective new drugs for MS with safety profiles that are distinct from those of currently approved drugs. Cyclophilin A is a protein that when secreted aids in attracting immune cells to sites of inflammation. It is not known whether cyclophilin A is specifically involved in CNS inflammation. Data from my laboratory showed that in an animal model of MS termed experimental allergic encephalomyelitis (EAE), treating animals with a drug that non-selectively blocks the action of cyclophilins reduces the severity of illness and reduces the number of immune cells that enter the CNS. To clearly define how cyclophilin inhibition improves CNS inflammation, we propose a study to test the hypothesis that cyclophilin A contributes to CNS inflammation by helping to recruit immune cells into the CNS.
In Aim 1 of the study, we propose to define the course and biology of EAE in mice that genetically lack cyclophilin A to test the hypothesis that the loss of cyclophilin A will impair recruitment of immune cells into the CNS and alter the type of immune response.
In Aim 2, we propose to test a novel compound that specifically inhibits extracellular cyclophilin A to test the hypothesis that blocking extracellular (secreted) cyclophilin A is sufficient to improve the course of EAE. The long-term goal of this proposal is to define how cyclophilins can be targeted for therapeutic purpose in MS. The objective of this proposal is to define the mechanism by which the loss of cyclophilin A reduces the disease burden in EAE and further define the role of cyclophilin A in CNS inflammation. Such results are expected to have an important positive impact by providing the knowledge needed to develop cyclophilin inhibitors as therapies for CNS inflammatory disorders such as MS, and thereby fulfill the NINDS mission to seek fundamental knowledge about the nervous system and to use that knowledge to reduce the burden of neurological disease.

Public Health Relevance

The long-term goal of this project is to improve treatment options for individuals living with multiple sclerosis. Using medications to block white blood cells from entering the brain and spinal cord has become an effective strategy to treat multiple sclerosis, but can be associated with serious side effects. The objective of this proposed research is to gain knowledge about a protein called cyclophilin A that may lead to new strategies to block white blood cells form entering the brain and spinal cord.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Research Grants (R03)
Project #
5R03NS098123-02
Application #
9418656
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Utz, Ursula
Project Start
2017-02-01
Project End
2019-01-31
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Neurology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298